It is well known that insulin and insulin secretagogues can lead to hypoglycemia. If dapagliflozin is used with insulin or an insulin secretagogue, the risk of hypoglycemia may worsen. Therefore, when these medications are combined with dapagliflozin, a lower dosage of insulin or an insulin secretagogue may be necessary to reduce the risk of hypoglycemia. Here, INS is linked to Hypoglycemia.